BGA — BioNeutra Global Income Statement
0.000.00%
Last trade - 00:00- CA$2.09m
- CA$8.84m
- CA$11.38m
- 43
- 78
- 24
- 46
Annual income statement for BioNeutra Global, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 37.7 | 24.1 | 15.4 | 13.4 | 11.4 |
| Cost of Revenue | |||||
| Gross Profit | 0.638 | 3.94 | 2.89 | 2.35 | 4.14 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 50.7 | 27.8 | 18.2 | 16.3 | 13.6 |
| Operating Profit | -13 | -3.68 | -2.83 | -2.88 | -2.26 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -13 | -3.77 | -2.83 | -2.92 | -2.11 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12.4 | -3.71 | -2.83 | -2.92 | -2.11 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.4 | -3.71 | -2.83 | -2.92 | -2.11 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.4 | -3.71 | -2.83 | -2.92 | -2.11 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.244 | -0.074 | -0.061 | -0.062 | -0.038 |